1. Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts 
Kile Green, Kim Pearce, Rob S. Sellar, Laura Jardine, Phillip L.R. Nicolson, Sandeep Nagra, Venetia Bigley, Graham Jackson, Anne M. Dickinson, Kirsty Thomson, Stephen Mackinnon, Charles Craddock, Karl S. Peggs, Matthew Collin 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 5, Pages (May 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Preparative regimens. Outline of preparative regimens for the 3 patient cohorts.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Overall incidence of acute GVHD. (A) Comparison of maximal acute GVHD grades between cohorts. No significant difference was detected by chi-square tests between cohorts. (B) Comparison of maximal acute GVHD grade between ≥10/10 and <10/10 matched unrelated donor transplants within each cohort. There were no significant differences by chi-square tests.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Incidence and severity of chronic GVHD. (A) Comparison of cumulative incidence of chronic GVHD analyzed with relapse and death as competing risks. Patients were censored at last follow-up. No significant difference was detected between cohorts. (B) Comparison of the maximal severity of chronic GVHD between cohorts. No significant difference was detected between cohorts.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Chimerism. (A) Donor T cell chimerism at 100 days. Bins of 0 to 50, 50 to 95, and 95 to 100 were selected based on the discontinuous data available for the 100-mg cohort. A significant difference was detected due to lower T cell chimerism in the 60-mg cohort. (B) Comparison of donor T cell chimerism at 100 days for patients in 50-mg and 60-mg cohorts showing skewing toward lower median T cell chimerism in the 60-mg cohort (Mann-Whitney test).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
CMV reactivation. The proportion of patients in each cohort requiring treatment for CMV reactivation, according to CMV risk status. A higher risk of reactivation was detected for high-risk CMV-positive recipients in the 100-mg cohort (*).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

7. Figure 6
Outcome. (A) Cumulative incidence of nonrelapse mortality with relapse as a competing factor showing no significant difference between the cohorts by Gray's test. (B) Cumulative incidence of relapse with nonrelapse mortality as a competing factor showing no significant difference between the cohorts by Gray's test. (C) Overall survival for patients with AML/MDS or NHL by cohort. Kaplan-Meier curves were compare by the log rank (Mantel-Cox) test.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions